Result:Poor· Market: Flat
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1.23 | 1032.8% | 93.9% |
| Total Income | 1.33 | 1559.7% | 93.4% |
| Expenditure | 4.32 | 11.2% | 80.5% |
| PBT | -3.47 | 12.7% | 84.6% |
| Net Profit | -3.58 | 14.1% | 83.0% |
| OPM | — | ||
| NPM | — | ||
| EPS | 0.71 | 14.5% | 83.2% |
Revenue collapsed 93.9% YoY to just ₹1.2 Cr and the company remains in a net loss (-₹3.58 Cr), so despite a smaller absolute loss than a year ago this reflects a near-total collapse of the core pharma business, not a turnaround.
Informational and educational content only. Not investment advice.